2. Peptides
  3. Peptide and Derivatives
  4. Peptides for Drug Delivery
  5. Peptide Conjugates

Peptide Conjugates

Custom Peptide Synthesis

Peptide conjugates include peptide–drug conjugates, peptide–chelator conjugates, etc. By linking peptides to other functional molecules, they are employed to facilitate targeted drug delivery, imaging, and related applications.

Peptide Conjugates (95):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106244
    DOTATATE 177943-88-3 99.95%
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE
  • HY-106244A
    DOTATATE acetate 177943-89-4 99.95%
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE acetate
  • HY-153549
    Pentixafor 1341207-62-2 99.79%
    Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging. Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pentixafor
  • HY-P10761
    DPI-4452 2941391-49-5 99.30%
    DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models. DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DPI-4452
  • HY-P5128
    DOTA-JR11 1039726-31-2 99.14%
    DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research. DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-JR11
  • HY-P11779
    Ac-RKAA-PABC-MMAE 2768774-89-4
    Ac-RKAA-PABC-MMAE is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE can be used for synthesis of ADCs.
    Ac-RKAA-PABC-MMAE
  • HY-P11591
    PDI2 3110124-60-9 99.00%
    PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.
    PDI2
  • HY-P11837
    NECT-224
    NECT-224 is a bifunctional chelator and a nectin-4 targeting peptide conjugate. NECT-224 can be used as a PET imaging agent when labeled with 64Cu or 68Ga.
    NECT-224
  • HY-P5126
    DOTA-LM3 1192362-32-5 99.37%
    DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3
  • HY-106033
    Edotreotide 204318-14-9 98.15%
    Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs).
    Edotreotide
  • HY-P4073
    ANG1005 1075214-55-9 98.83%
    ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system.
    ANG1005
  • HY-P10131
    3BP-3940 2803421-14-7 99.49%
    3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
    3BP-3940
  • HY-164725
    FAPI-mFS 3023869-94-2 98.71%
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu. FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-P5362
    NODAGA-LM3 99.65%
    NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors.
    NODAGA-LM3
  • HY-P10920
    DOTAMTATE 2415661-92-4 99.55%
    DOTAMTATE is a somatostatin analogue. DOTAMTATE marked 212Pb is promising for research of somatostatin receptor positive neuroendocrine tumors.
    DOTAMTATE
  • HY-P2112
    DOTA-NOC 619300-53-7 99.22%
    DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging. DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-NOC
  • HY-P5018
    NOTA-AE105 1820563-84-5 98.99%
    NOTA-AE105 is a PET ligand for the urokinase-type plasminogen activator receptor (uPAR). NOTA-AE105 can be radiolabeled with 64Cu and 68Ga. Images of 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 demonstrate high contrast and clear tumor delineation. NOTA-AE105 can be used in the synthesis of radionuclide-conjugated compounds (RDCs).
    NOTA-AE105
  • HY-D2363
    DOTA.SA.FAPi TFA 99.26%
    DOTA.SA.FAPi TFA is a selective FAP inhibitor with an IC50 value of 0.9 nM against FAP. DOTA.SA.FAPi TFA forms stable complexes with 68Ga and serves as a PET radiotracer for preclinical imaging of FAP-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers.
    DOTA.SA.FAPi TFA
  • HY-P10273A
    DOTA-Octreotide TFA 99.50%
    DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-Octreotide TFA
  • HY-P10758
    Alkyne-βAG-TOCA 98.99%
    Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2). Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Alkyne-βAG-TOCA